Evidence map›Paper›PMID 38101910›Full record

ArticleThe Journal of rheumatology2024

Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies.

Joshua J Skydel, Reshma Ramachandran, Sakinah Suttiratana, Joseph S Ross, Christopher M Burns, Joshua D Wallach

Abstract readLetter
In one paragraph

Article in The Journal of rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joshua J SkydelDartmouth Hitchcock Medical Center, Lebanon, New Hampshire; joshua.j.skydel@hitchcock.org.ORCID 0000-0002-3527-4277
Reshma RamachandranSection of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, and Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0003-3845-3606
Sakinah SuttiratanaDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.ORCID 0000-0001-9775-7736
Joseph S RossSection of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Department of Health Policy and Management, Yale School of Public Health, New Haven, and Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-9218-3320
Christopher M BurnsSection of Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
Joshua D WallachDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.ORCID 0000-0002-2816-6905

Funding

Identifying Patient Subgroups That Are Most Likely To Benefit From Medications Used To Treat Alcohol Use DisorderK01AA028258 · NIAAA · YALE UNIVERSITY · PI WALLACH, JOSHUA DAVID · 2021 to 2025
$892k
NIAAA NIH HHS K01 AA028258
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DemographyLupus Erythematosus, SystemicClinical Trials as TopicDrug IndustryHumans

Identifiers

PMID38101910
PMCPMC10922605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.